Can PCPs Prescribe GLP-1? Clinical Criteria & Biomarkers

Last reviewed: May 21, 2026

Last updated: May 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, primary care physicians can prescribe GLP-1 receptor agonists for weight management and type 2 diabetes when clinical criteria are met. The FDA has approved several GLP-1 medications for chronic weight management in adults with obesity or overweight status, and PCPs play an increasingly central role in identifying appropriate candidates and monitoring treatment outcomes.

Understanding whether a PCP can prescribe GLP-1 and evaluating your candidacy requires more than eligibility—it involves assessing your metabolic profile, cardiovascular risk factors, and treatment goals. PlexusDx supports this precision-wellness approach by offering patients insights into genetic predispositions in peptide pathways, helping inform a data-driven conversation with their PCP about whether GLP-1 treatment aligns with their individual biology.

PCP Prescribing Authority and Clinical Scope

PCPs operate within scope-of-practice guidelines that generally permit prescription of FDA-approved GLP-1 medications. However, prescribing authority varies by state licensing laws, insurance requirements, and individual practice protocols. Many PCPs routinely prescribe GLP-1 agonists for type 2 diabetes management; prescribing for chronic weight management is increasingly common but may require additional patient education and monitoring.

PCPs are uniquely positioned to evaluate GLP-1 candidacy because they understand a patient's full medical history, medication interactions, and comorbidities. A comprehensive PCP assessment typically includes BMI evaluation, metabolic markers, cardiovascular risk, family history of diabetes, and contraindication screening before initiating GLP-1 therapy.

Clinical Eligibility Criteria PCPs Use to Evaluate GLP-1 Candidacy

PCPs evaluate GLP-1 candidacy using evidence-based clinical criteria established by the American Diabetes Association, American Academy of Family Physicians, and specialty guidelines. These criteria assess metabolic status, cardiovascular risk, and treatment goals to determine if GLP-1 aligns with a patient's health profile and whether it offers benefit beyond current management strategies.

Criterion	Clinical Context
BMI or Weight Status	BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities (hypertension, dyslipidemia, sleep apnea) for weight management; any BMI for type 2 diabetes management.
Metabolic Profile	Fasting glucose, HbA1c, and insulin resistance assessment; higher baseline glucose or HbA1c may indicate greater GLP-1 benefit.
Cardiovascular Risk	History of cardiovascular disease, hypertension, or high cardiovascular risk score may increase clinical benefit; GLP-1s reduce CV events in high-risk patients.
Kidney and Thyroid Function	Estimated GFR ≥15 mL/min/1.73 m² required; no personal or family history of medullary thyroid cancer or MEN2 syndrome.

Biomarker Context and Metabolic Assessment Before Starting GLP-1

Beyond standard clinical criteria, baseline biomarker assessment helps PCPs predict GLP-1 responsiveness and tailor dosing strategies. Key biomarkers include fasting insulin, HOMA-IR (insulin resistance index), C-peptide, and inflammatory markers like CRP, which correlate with GLP-1 mechanism engagement and weight loss trajectories.

Some patients exhibit greater GLP-1 efficacy based on their baseline metabolic state. Those with higher baseline insulin levels or insulin resistance may experience greater weight loss and metabolic improvement, while those with borderline glucose control may benefit more from cardiovascular and incretin effects. PCPs increasingly order these biomarkers to support informed patient discussions about realistic outcomes and timeline.

When PCPs Refer to Specialists and Safety Monitoring Protocols

PCPs manage many GLP-1 patients independently, but referral to endocrinologists, cardiologists, or obesity medicine specialists is appropriate for complex cases: severe renal impairment, active cardiovascular disease, concurrent use of insulin, or inadequate response to initial dosing. Specialist input clarifies risk-benefit ratio and dosing optimization in these scenarios.

PCP monitoring includes baseline and periodic assessment of gastrointestinal tolerability, glycemic control, weight response, kidney function, and cardiovascular symptoms. Patients should report persistent nausea, vomiting, dehydration, or unusual thyroid symptoms. PCPs adjust dose, pause treatment, or discontinue based on clinical response and tolerability.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context by revealing genetic predispositions in key peptide pathways—including GLP-1 receptor (rs6923761), GIPR receptor (rs1800437), and metabolic regulators like FTO (rs9939609) and MC4R (rs17782313). These variants can illuminate your baseline metabolic biology and how your genetic profile aligns with GLP-1 mechanism of action.

The genetic test identifies predispositions in peptide-related pathways, not exact medication response or efficacy. Certain variants may be associated with metabolic phenotypes that respond differently to GLP-1 agonists. This information should be interpreted with a qualified healthcare provider and used to support a more personalized conversation about treatment candidacy and expected outcomes.

Understanding your genetic predispositions in GLP-1 and GIPR pathways can support a more informed discussion with your PCP about whether GLP-1 treatment aligns with your metabolic biology. Combining genetic insights with clinical biomarkers, medical history, and PCP expertise creates a comprehensive foundation for shared decision-making about treatment initiation.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.